Contact Supplier

Contact Supplier

To get in touch with enGenes Biotech GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    enGenes Biotech bringing enhanced product yield opportunities to BIO-Europe Autumn in Germany

    news-releasesenGenes Biotech GmbH
    October 21st 2022

    Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will present its latest technologies at the upcoming annual BIO-Europe Autumn biotech industry partnering conference in Leipzig, Germany.

    enGenes will share an exhibition booth with LISAvienna, the life science platform jointly operated by the Austrian Federal Ministry of Labour and Economy and the City of Vienna that is dedicated to advancement of the Viennese life sciences community, of which enGenes is a prominent member.

    Maximized expression

    Through its exhibitor presence and active networking at the conference, enGenes will communicate the opportunities to maximise product yields, including production of difficult to express biomolecules, using its proprietary  -eXpress platform technology.

    enGenes will be represented at BIO Europe in Leipzig by its head of Business Development, Dr. Karl Hübler, along with Senior Scientist Dr. Patrick Stargardt.

    Prominent BIO presence

    “enGenes has become a well-recognized presence at BIO industry events, since we have attended every conference since 2014,” commented Dr. Hübler,.

    “Once again we will be taking full advantage of the partneringONE platform and many networking events here to create face-to-face meetings and widen the range of our partnerships and collaborations,” he added.

    “This year, more than ever before, we will be able to show how we can offer very cost-effective manufacturing solutions to our client’s particular issues. Our enGenes -eXpress technology offers protein secretion that allows cost-effective downstream processing from E. coli cell free supernatants. We can also offer an innovative solution for bioconjugation that can site specifically modify recombinant proteins,” Dr. Hübler noted.

    About enGenes Biotech

    enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

    enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes -eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

    enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

    About BIO-Europe Autumn 2022

    BIO-Europe Autumn® is a premier partnering conference hosted twice annually by the international BIO Biotechnology organization that attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

    The three-day Autumn 2022 event opens on October 24 at the Leipzig Messe conference center in eastern Germany with a further three days as an online event from November 2.

    Featuring a sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

    The conference is expected to attract more than 4,500 actively participating delegates from some 50 countries worldwide. It will feature more than 20 workshops and panels with more than 3,600 licensing opportunities posted.

    The event is organized by EBD Group (Informa Connect), with further information at:


    Click on Partnering with enGenes for further information.


    Meet the Partners - Co-Founder - Juergen Mairhofer

    enGenes Biotech bringing enhanced product yield opportunities to BIO-Europe Autumn in Germany

    Contact enGenes Biotech GmbH

    Simply fill out the form below to contact enGenes Biotech GmbH now.

    Send enGenes Biotech GmbH a Message